ClinicalTrials.gg
RecruitingNCT07069595PREDICT-RDUpdated Nov 13, 2026

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

A Phase 2 interventional study of Datopotamab deruxtecan and Circulating tumor DNA (ctDNA) testing in Breast Cancer, Residual Disease and Triple Negative Breast Cancer (TNBC), sponsored by UNC Lineberger Comprehensive Cancer Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UNC Lineberger Comprehensive Cancer Center · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Nov 13, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 159 open to participants now, 263 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
239th of 605
78 · median 52
Started
2026
with 37 others
Phase 2
191 of 645
45 open now
Primary completion
2031-11
later than 253 of 262 live
Registered
596th of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 239th largest by planned enrollment of the 605 interventional ones that give a count, is one of 38 that started in 2026, is one of 191 in phase 2, reaches primary completion later than 253 of the 262 other live ones, and was the 596th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

159 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery. Technological advances in ctDNA assays have improved both the sensitivity and reliability of molecular residual disease (MRD) detection to enable real-time measurement with clinical-grade assays.

The primary objective of this study will be to evaluate ctDNA-based MRD status in high-risk, early-stage TNBC patients by defining the proportion of TNBC patients with MRD-only recurrence (ctDNA positive without radiographically measurable recurrence) during post-surgery surveillance. The secondary objectives will evaluate the safety, preliminary efficacy, and survival outcomes of using Dato-DXd in participants with MRD-only TNBC.

Dato-DXd is an investigational antibody-drug conjugate (monoclonal antibody specific for TROP2 and a topoisomerase I (Topo-1) inhibitor) that has demonstrated promising efficacy in TNBC patients with a manageable safety profile.

Read the detailed description

Despite treatment advances, patients with II/III triple negative breast cancer (TNBC) residual disease post-neoadjuvant therapy, particularly patients with higher residual cancer burden (RCB II/III), remain at high risk for developing recurrence. Furthermore, early detection of relapse risk, when the residual disease burden is micrometastatic (defined here as undetectable by standard cross-sectional imaging), provides a chance for disease eradication whereas macrometastatic disease (i.e., detectable on standard cross-sectional imaging) is generally considered to be non-curable.

There are no standard of care (SOC) surveillance strategies for early detection of micrometastatic disease in high-risk TNBC beyond clinical monitoring. Detecting molecular residual disease (MRD) is a promising approach to identifying patients at increased risk of recurrence after definitive therapy, who may benefit from the escalation of their treatment and remain potentially curable with effective systemic therapy.

03

Conditions studied

  • Breast Cancer
  • Residual Disease
  • Triple Negative Breast Cancer (TNBC)
  • Stage II/III

Browse trials for

Keywords

  • circulating tumor DNA (ctDNA)
  • surveillance
  • Dato-DXd
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 78 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Written was obtained to participate in the study, and HIPAA authorization for the release of personal health information.

  • Participant is willing and able to comply with study procedures based on the judgment of the investigator.
  • Age ≥ 18 years at the time of consent.
  • Histological confirmation of TNBC defined by ER/PR \<10%, 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative.
  • Stage II/III TNBC treated with systemic therapy AND have residual disease defined as RCB II/III at time of surgery.
  • Baseline staging scans at the discretion of the treating physician and demonstrate no evidence of disease.
  • The participant must have archival diagnostic tissue and/or surgical resection tissue Available.
  • Participants are willing and able to comply with study procedures based on the judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Participants are pregnant or breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Patients with higher residual cancer burden

    Participants with stage II/III triple negative breast cancer (TNBC) and residual disease post-neoadjuvant therapy, particularly patients with higher residual cancer burden (RCB II/III), remain at high risk for developing recurrence.

    Drug: Datopotamab deruxtecan · Diagnostic Test: Circulating tumor DNA (ctDNA) testing

Interventions

  • Dato-DXd is administered adjuvantly at 6 mg/kg IV for eight cycles.

    Also known as: Dato-DXd

  • Diagnostic testCirculating tumor DNA (ctDNA) testing

    Circulating tumor DNA (ctDNA) testing is a type of biopsy that analyzes fragments of DNA shed by cancer cells into the bloodstream. These fragments, known as ctDNA, can provide valuable information about the genetic makeup of a tumor without needing a traditional tissue biopsy.

07

What researchers measure

Primary outcomes

  1. The proportion of triple negative breast cancer (TNBC) with molecular residual disease (MRD)

    The number of participants with triple negative breast cancer (TNBC) with molecular residual disease (MRD) only recurrence, which is defined as ctDNA positivity without radiographically measurable recurrence, during post-surgery surveillance.

    Time frame: Up to 3 years after registration

Secondary outcomes

  1. The time between Circulating tumor DNA (ctDNA) positivity and clinically proven relapse

    ctDNA levels will be measured every 6 weeks during adjuvant and/or Dato-DXd therapy and every 12 weeks thereafter.

    Time frame: Up to 3 years after registration

  2. Duration of Circulating tumor DNA (ctDNA) clearance

    Duration of ctDNA clearance will be defined as the time from the first confirmed clearance (for negative test after positive results) to the date of confirmed positivity.

    Time frame: Up to 3 years after registration

  3. Circulating tumor DNA (ctDNA) clearance with Dato-DXd

    ctDNA clearance in participants who receive Dato-DXd will be defined as the proportion of participants who convert from ctDNA positive to negative after initiation of Dato-DXd.

    Time frame: Up to 3 years after registration

  4. Toxicity of Dato-DXd

    Toxicity of Dato-DXd treatment will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. NCI-CTCAE is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

    Time frame: Up to 3 years after registration

  5. Recurrence Free Survival (RFS) for ctDNA-positive and ctDNA-negative disease.

    RFS will be measured from the day of the first circulating tumor DNA (ctDNA) measurement to documented recurrence of disease in participants with ctDNA-positive and ctDNA-negative disease.

    Time frame: Up to 3 years after registration

  6. Recurrence Free Survival (RFS) - Dato-DXd

    RFS will be measured from the day of the first circulating tumor DNA (ctDNA) measurement to documented recurrence of disease in participants who receive Dato-DXd.

    Time frame: Up to 3 years after registration

  7. Overall Survival (OS) - ctDNA-positive and ctDNA and negative disease.

    OS will be measured from the day of the first ctDNA measurement to death from any cause in participants with ctDNA-positive and ctDNA-negative disease.

    Time frame: Up to 3 years after registration

  8. Overall Survival (OS) - for ctDNA-positive and ctDNA-negative disease.

    OS will be measured from the day of the first ctDNA measurement to death from any cause in participants who receive Dato-DXd.

    Time frame: Up to 3 years after registration

08

Study locations

2 of 2 sites recruiting
  • O'Neal Comprehensive Cancer Center/The University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
    Recruiting
    • Anna Wilbanks · Contactannaburton@uabmc.edu · 205-644-9876
    • Erica Stringer-Reasor, MD · Principal investigator
  • UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27514, United States
    Recruiting
09

References and documents

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2031, 68 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 68 months is above that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 16, 2025
StartActual
Feb 26, 2026
Primary completionEst.
Nov 1, 2031
CompletionEst.
Nov 1, 2032
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • O'Neal Comprehensive Cancer Center/The University of Alabama at Birmingham · Birmingham, United States
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    1 site added
    Show site
    • O'Neal Comprehensive Cancer Center/The University of Alabama at Birmingham · Birmingham, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07069595
Collaborators
AstraZeneca, Translational Breast Cancer Research Consortium
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Feb 26, 2026
Primary completion
Nov 1, 2031 (estimated)
Completion
Nov 1, 2032 (estimated)
Last update
Nov 13, 2026

Study contacts

Taylor Pierce
Contact
Taylor_Pierce@med.unc.edu
(919) 445-4827
Yara Abdou, MD
principal investigator · UNC Lineberger Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion